medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2014, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2014; 61 (2)

Profile of bacterial resistance in blood cultures performed in Mexican population in the years 2009 to 2011

Rodríguez MSE, Cervantes-Villagrana AR, Castañeda-Delgado JE, Presno-Bernal JM, Cervantes-Villagrana RD

Language: Spanish
References: 19
Page: 108-114
PDF size: 266.70 Kb.


ABSTRACT

Antibiotics resistance is a health problem worldwide, which is characterized by low or no effective treatments against bacterial infections that increase morbidity and mortality in septicemia patients. In Mexico, part of the problem has been attributed to self-medication and uncontrolled antibiotics sale. Today is necessary to emphasize regulation of pharmaceuticals classified as generic or similar drugs because they lack of quality control, which may cause low effectiveness of the drug and thus promote drug resistance in the Mexican population. In this paper we analyzed the drug resistance prevalence in bacteria identified in hemocultures obtained of patients with septicemia from Mexico City. We found that drugs such as linezolid, imipenem and gatifloxacin are the most effective drugs against bacterial strains with the highest rate of drug resistance in this population. However, penicillins were less effective drugs because of drug resistant bacteria. We also found that the bacteria with more drug resistance index in our studies were Staphylococcus hominis, Acinetobacter baumannii and Pseudomonas aeruginosa.


REFERENCES

  1. Acar JF, Goldstein FW. Consequences of increasing resistance to antimicrobial agents. Clin Infect Dis. 1998; 27 (suppl 1): S125-S130.

  2. Heymann D, Dzenowagis J. Commentary: Emerging and other communicable diseases. Bull World Health Organ. 1998; 76 (6): 545-547.

  3. Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med. 2000; 133 (2): 128-135.

  4. Benavides-Plascencia L, Aldama-Ojeda AL, Javier Vazquez H. Surveillance of antibiotic utilization and bacterial resistance profiles in tertiary level hospitals in Mexico City. Salud Pública Mex. 2005; 47 (3): 219-226.

  5. Dreser A, Wirtz VJ, Corbett KK, Echaniz G. Antibiotic use in Mexico: review of problems and policies. Salud Pública Mex. 2008; 50 (suppl 4): S480- S487.

  6. Jones RN, Fritsche TR, Moet GJ. In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn, Wyeth) formulation. Diagn Microbiol Infect Dis. 2008; 61 (1): 76-79.

  7. Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother. 2003; 15 (4): 357-368.

  8. Amabile-Cuevas C. Antibiotic resistance in Mexico: a brief overview of the current status and its causes. J Infect Dev Ctries. 2010; 4 (3): 126-131.

  9. Martin CP, Talbert RL, Burgess DS, Peters JI. Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation. Pharmacotherapy. 2007; 27 (1): 20-26.

  10. Pradipta IS, Sodik DC, Lestari K, Parwati I, Halimah E, Diantini A et al. Antibiotic resistance in sepsis patients: evaluation and recommendation of antibiotic use. N Am J Med Sci. 2013; 5 (6): 344-352.

  11. Meletis G, Exindari M, Vavatsi N, Sofianou D, Diza E. Mechanisms responsible for the emergence of carbapenem resistance in Pseudomonas aeruginosa. Hippokratia. 2012; 16 (4): 303-307.

  12. Mendoza-Olazaran S, Morfin-Otero R, Rodriguez-Noriega E, Llaca-Diaz J, Flores-Trevino S, Gonzalez-Gonzalez GM et al. Microbiological and molecular characterization of Staphylococcus hominis isolates from blood. PLoS One. 2013; 8 (4): e61161.

  13. de Almeida LM, de Araujo MR, Sacramento AG, Pavez M, de Souza AG, Rodrigues F et al. Linezolid resistance in Brazilian Staphylococcus hominis strains is associated with L3 and 23S rRNA ribosomal mutations. Antimicrob Agents Chemother. 2013; 57 (8): 4082-4083.

  14. Rumbo C, Gato E, Lopez M, Ruiz de Alegria C, Fernandez-Cuenca F, Martinez-Martinez L et al. The contribution of efflux pumps, porins and beta-lactamases to multi-drug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013; 12.

  15. Lopez-Salas P, Llaca-Diaz J, Morfin-Otero R, Tinoco JC, Rodriguez-Noriega E, Salcido-Gutierres L et al. Virulence and antibiotic resistance of Enterococcus faecalis clinical isolates recovered from three states of Mexico. Detection of linezolid resistance. Arch Med Res. 2013; 21.

  16. Flamm RK, Mendes RE, Ross JE, Sader HS, Jones RN. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother. 2013; 57 (2): 1077-1081.

  17. Chen H, Wu W, Ni M, Liu Y, Zhang J, Xia F et al. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms. Int J Antimicrob Agents. 2013; 20.

  18. Gutierrez O, Juan C, Cercenado E, Navarro F, Bouza E, Coll P et al. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother. 2007; 51 (12): 4329-4335.

  19. Yang XJ, Chen Y, Yang Q, Qu TT, Liu LL, Wang HP et al. Emergence of cfr-harbouring coagulase-negative staphylococci among patients receiving linezolid therapy in two hospitals in China. J Med Microbiol. 2013; 62 (Pt 6): 845-850.




2020     |     www.medigraphic.com